Cargando…

Remarkable response to abiraterone acetate in castration‐resistant prostate cancer patient with aggressive liver metastasis

INTRODUCTION: The number of treatment options for metastatic castration‐resistant prostate cancer has increased in recent years. Abiraterone, which selectively inhibits CYP17 in the androgen synthesis pathway, is widely used. Liver metastasis is one of the worst prognostic factors in metastatic cast...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsui, Masahiro, Ohigashi, Takashi, Kosaka, Takeo, Bessho, Hideharu, Arakawa, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292117/
https://www.ncbi.nlm.nih.gov/pubmed/32743362
http://dx.doi.org/10.1002/iju5.12026
_version_ 1783546041765724160
author Katsui, Masahiro
Ohigashi, Takashi
Kosaka, Takeo
Bessho, Hideharu
Arakawa, Takashi
author_facet Katsui, Masahiro
Ohigashi, Takashi
Kosaka, Takeo
Bessho, Hideharu
Arakawa, Takashi
author_sort Katsui, Masahiro
collection PubMed
description INTRODUCTION: The number of treatment options for metastatic castration‐resistant prostate cancer has increased in recent years. Abiraterone, which selectively inhibits CYP17 in the androgen synthesis pathway, is widely used. Liver metastasis is one of the worst prognostic factors in metastatic castration‐resistant prostate cancer. Only a few case reports have shown abiraterone successfully treated the liver metastasis of metastatic castration‐resistant prostate cancer. CASE PRESENTATION: A 62‐year‐old man with prostate‐specific antigen of 16.69 ng/mL was diagnosed with Gleason 8 (3 + 5) poorly differentiated prostate adenocarcinoma. Androgen deprivation therapy and sequential anti‐androgen replacement were performed; however, the disease advanced to castration‐resistant prostate cancer with liver metastasis. Prior to docetaxel, abiraterone achieved marked improvements in liver metastasis and prostate‐specific antigen. CONCLUSION: Metastatic castration‐resistant prostate cancer patients with visceral metastasis were excluded from COU‐AA‐302, which is phase III trial on abiraterone prior to docetaxel. Although docetaxel is the recommended treatment for the visceral metastasis of castration‐resistant prostate cancer according to the European Association of Urology guidelines, abiraterone also has potential as a treatment option.
format Online
Article
Text
id pubmed-7292117
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-72921172020-07-30 Remarkable response to abiraterone acetate in castration‐resistant prostate cancer patient with aggressive liver metastasis Katsui, Masahiro Ohigashi, Takashi Kosaka, Takeo Bessho, Hideharu Arakawa, Takashi IJU Case Rep Case Reports INTRODUCTION: The number of treatment options for metastatic castration‐resistant prostate cancer has increased in recent years. Abiraterone, which selectively inhibits CYP17 in the androgen synthesis pathway, is widely used. Liver metastasis is one of the worst prognostic factors in metastatic castration‐resistant prostate cancer. Only a few case reports have shown abiraterone successfully treated the liver metastasis of metastatic castration‐resistant prostate cancer. CASE PRESENTATION: A 62‐year‐old man with prostate‐specific antigen of 16.69 ng/mL was diagnosed with Gleason 8 (3 + 5) poorly differentiated prostate adenocarcinoma. Androgen deprivation therapy and sequential anti‐androgen replacement were performed; however, the disease advanced to castration‐resistant prostate cancer with liver metastasis. Prior to docetaxel, abiraterone achieved marked improvements in liver metastasis and prostate‐specific antigen. CONCLUSION: Metastatic castration‐resistant prostate cancer patients with visceral metastasis were excluded from COU‐AA‐302, which is phase III trial on abiraterone prior to docetaxel. Although docetaxel is the recommended treatment for the visceral metastasis of castration‐resistant prostate cancer according to the European Association of Urology guidelines, abiraterone also has potential as a treatment option. John Wiley and Sons Inc. 2018-11-12 /pmc/articles/PMC7292117/ /pubmed/32743362 http://dx.doi.org/10.1002/iju5.12026 Text en © 2018 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Reports
Katsui, Masahiro
Ohigashi, Takashi
Kosaka, Takeo
Bessho, Hideharu
Arakawa, Takashi
Remarkable response to abiraterone acetate in castration‐resistant prostate cancer patient with aggressive liver metastasis
title Remarkable response to abiraterone acetate in castration‐resistant prostate cancer patient with aggressive liver metastasis
title_full Remarkable response to abiraterone acetate in castration‐resistant prostate cancer patient with aggressive liver metastasis
title_fullStr Remarkable response to abiraterone acetate in castration‐resistant prostate cancer patient with aggressive liver metastasis
title_full_unstemmed Remarkable response to abiraterone acetate in castration‐resistant prostate cancer patient with aggressive liver metastasis
title_short Remarkable response to abiraterone acetate in castration‐resistant prostate cancer patient with aggressive liver metastasis
title_sort remarkable response to abiraterone acetate in castration‐resistant prostate cancer patient with aggressive liver metastasis
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292117/
https://www.ncbi.nlm.nih.gov/pubmed/32743362
http://dx.doi.org/10.1002/iju5.12026
work_keys_str_mv AT katsuimasahiro remarkableresponsetoabirateroneacetateincastrationresistantprostatecancerpatientwithaggressivelivermetastasis
AT ohigashitakashi remarkableresponsetoabirateroneacetateincastrationresistantprostatecancerpatientwithaggressivelivermetastasis
AT kosakatakeo remarkableresponsetoabirateroneacetateincastrationresistantprostatecancerpatientwithaggressivelivermetastasis
AT besshohideharu remarkableresponsetoabirateroneacetateincastrationresistantprostatecancerpatientwithaggressivelivermetastasis
AT arakawatakashi remarkableresponsetoabirateroneacetateincastrationresistantprostatecancerpatientwithaggressivelivermetastasis